AI Verdict
IONS has stronger fundamentals based on our AI analysis.
IOVA vs IONS Fundamental Comparison
| Metric | IOVA | IONS |
|---|---|---|
| Revenue | $263.5M | $203.3M |
| Net Income | $-391.0M | $-381.4M |
| Net Margin | -148.4% | -187.6% |
| ROE | -56.0% | -78.0% |
| ROA | -42.8% | -10.8% |
| Current Ratio | 3.20x | 3.83x |
| Debt/Equity | 0.00x | 3.71x |
| EPS | $-1.09 | $-2.38 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
IOVA vs IONS: Frequently Asked Questions
Is IOVA or IONS a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), IONS has stronger fundamentals. IOVA is rated STRONG SELL (92% confidence) while IONS is rated SELL (85% confidence). This is not investment advice.
How does IOVA compare to IONS fundamentally?
IOVANCE BIOTHERAPEUTICS, INC. has ROE of -56.0% vs IONIS PHARMACEUTICALS INC's -78.0%. Net margins are -148.4% vs -187.6% respectively.
Which stock pays higher dividends, IOVA or IONS?
IOVA has a dividend yield of N/A or no dividend while IONS has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in IOVA or IONS for long term?
For long-term investing, consider that IOVA has STRONG SELL rating with 92% confidence, while IONS has SELL rating with 85% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about IOVA vs IONS?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For IOVA vs IONS, the AI consensus favors IONS based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.